Reanalyzing the TCGA BLCA cohort data, we demonstrated that compared to patients without metastasis (M0), MED10 expression is upregulated in metastatic disease (M1) (Figure 2A). This evidence concerns the gene MED10 and bladder transitional cell carcinoma.